Vedico Pharmacologistic Ltd.

Vedico Pharmacologistic Ltd. is a newly founded importer and wholesaler for international pharmaceuticals, food subliments, health care products and baby food in Africa

Our suppliers are international well known manufacturers, which are commited to highest and save quality meeting WHO- and other international standards.

As a mediator between the industry and the specialist retailer our goal is to serve our customers by frequently deliveries in time out of a permanent stock at side and to set up a africanwide wholesale structure with local import partners.


Anti-Malaria-Products

For the fight against Malaria, we are offering high quality drugs on the basis of Arteminisin:

Arterakine












Artesunat injection (60mg/ml)

Presentation:
- Box of 1 vial of artesunat 60 mg + 1 ampule of sodium bicarbonat 50 mg/1 ml
- Box of 1 vial of artesunat 60 mg + and 1 ampule of sodium bicarbonat 50 mg/1 ml + 1 ampule of sodium clorid 0,9%

Actions:
Artesunate (C19H28O8) is an antimalarial agents. Artesunate is a derivative of Artemisinin found in Artemisia annua, a herb that has traditionally been used in Vietnam for the treatment of malaria. Artesunat mainly acts on asexual body of eryghrocytic-stage plasmodium and is the only effective derivatives of artemisinin at present that can be made into water-soluble preparation. It is used for all kinds of malarias, especially for malignant malarias with multi drug-resistance. It is first choice to treat severe malaria. It has the characteristics of rapid effect, high efficiency, low toxin, and multi administration route.

Indication:
Artesunate has an antimalrial activity. It can quickly and reliably control the actute attack and cerebral type of malaria. It is effective against plasmodium falciparum and plasmodium vivax, especially against malaria parasites resistant to Chlorquine.

Administration:
- As prescribed by physicians.
- It can be given by deep IM injection or slow IV injection:
+ Deep IM injection: Dissolve 60mg of Artesunate with 1ml of 5% sodium bicarbonate solution for injection before use.
+ Slow IV injection: Dissolve 60mg of Artesunate with 1ml of 5% sodium bicarbonate solution for injection and add 5ml of 0.9% sodium chloride solution for injection before use to make 1ml contains 10mg of Artesunate. Injection must follow immediately soon after dissolution, if the solution appears cloudy or sediment occurs, it should be rejected.

Dosage:
The usual injection dosage for each time:
- Adult and Children > 7 years: 1.2mg/kg.
- Children < 7 years: 1.5mg/kg.
The following doses are given at hour 4 and 24 after the first injection in day 1. Give 1 dose daily for the consecutive days. A course of therapy is recommended for 5 consecutive days.

Contraindications:
No contra-indications has been so far reported.

Side effects:
The most frequent side-effect are mild, transient such as: side-effects on gastrointestinal system (nausea, abdominal pain, diarrhea), headache, dazzling...

Precautions:
Use with caution in pregnant women in the first trimester.

Interactions:
Due to its structure containing a sesquiterpene lactone that bears a peroxide grouping which releases free oxygen, avoid using Artesunate concomitantly with antioxidants such as Vitamin E, Vitamin C, Glutathione, ... because those will decrease the antimalarial action of the drug.

Self-life:
36 months from the manufacturing date.
Never use after the expiry date clearly indicated on the outer packaging.

Storage:
Store in a cool, dry place. Protect from light.


Artesunat 50 mg tablets

Presentation:
- Box of 1 blister of 12 tablets.
- Box of 10 blisters of 12 tablets.

Compositions:
Each tablet contains: Artesunat: 50mg

Indications:
ARTESUNAT is a preparation for killing the asexual forms of Plasmodim at erythrocytic stage. It is effective against Plasmodium falciparum and Plasmoduim vivax, epecially against malarial parasites resistant to Chloroquine. ARTESUNAT can quickly and reliably control the acute attack and cerebral type of malaria.

Dosage & administration:
As prescribed by physicians.

* Adults:
12 tablets: for 5 days (4, 2, 2, 2, 2). The dose of first day should be double.

* Children:
1-3 years: 3 tablets for 5 days (1/2, 1/2, 1/2, 1/2, 1/2).
3-5 years: 6 tablets for 5 days (2. 1, 1, 1, 1,).
6-12 years: 8 tablets for 5 days (3, 2, 1, 1,).

Side-effects 
The most frequent side-effect are mild and transient.
Inform your doctor about side-effects when using this medicine.

Precautions:
Pregnant women less than 3 months should not use except for serious malaria and pernicious malaria.

Shelf-life:
36 months from the manufacturing date.
Never use after the expiry date clearly indicated on the outer packaging.

Storage:
Store in a cool, dry place. Protect from light


Artemether

Group:
Anti-malaria drug.

Dosage and content:
Syringe 40mg/ml, 80 mg / 1 ml. Artemether in refined coconut oil.

Indication:
Artemether is indicated for the treatment of malaria caused by all kinds of Plasmodium, including severe malaria caused by multi-resistant Plasmodium falciparum
Artemether is a effective drug in treating malaria, but only use artemether when other anti-malaria drug does not work and must take full dose.

Contra- indications:
Contraindication are not known clearly.

Pregnancy:
Experience on the human are limited, especially in the early stages of pregnancy. No side effects have meaning in 23 children born of mothers who have used artemether in the period of 16th-38th week of pregnancy. Thus drugs can be used for pregnancy has cerebral malaria or malaria in areas may be complicated caused by multi-resistant Plasmodium falciparum.

Lactation:
Not known how the drug transfer into breast milk. But should stop breastfeeding if the mother is treated with artemether.

ADR:
Using a total dose of 700 mg did not show side effects. Millions of people have used artemether, but no serious harmful effects. Have reported on the changes the test parameters, such as reducing red grid, increased transaminase and changes on electrocardiogram. May occur abdominal pain, nausea, vomiting, diarrhea, and tinnitus. However, these changes are only transient. Have not seen the neurological toxicity in humans.
Dealing with ADR contructions:
The drug dose should be sufficient to protect against recurrence.
When severe malaria, to extend treatment to 7 days.

Dosage and usage
Only used for adults and children over 6 months old. Be severe malaria or complications:
Method 1:
Day 1: intramuscular 3.2 mg / kg / day, four days after: 1.6 mg / kg / day.
Method 2:
Day 1: intramuscular 3.2 mg / kg / day. After that day intramuscular injection 1.6 mg / kg until the patient can use the pill in oral, swith to use oral or ?nective anti-malaria drugs, but not exceed 7 days.
Only use arthemether once a day. When inject for children, use 1 ml tuberculin syringe, for injecting small doses.

Stability and preservation:
To avoid light, avoid heat, stored at room temperature. If so long in cold temperatures, can be precipitated, but can be melt if left at room temperature. If precipitation does not dissolve completely, must be discarded.

Shelf life:
24 months from the date of manufacture.

Incompatibleness:
Artemether can be used in combination with other anti - malaria drugs especially with mefloquin.

Overdose and treatment position:
Using overdose, need treatment for symptoms of poisoning in the emergency room. There is no specific antidote.


ACTwide

Group:
Anti-malaria drug.

Dosage and content:
Syringe 40mg/ml, 80 mg / 1 ml. Artemether in refined coconut oil.

Indication:
Artemether is indicated for the treatment of malaria caused by all kinds of Plasmodium, including severe malaria caused by multi-resistant Plasmodium falciparum
Artemether is a effective drug in treating malaria, but only use artemether when other anti-malaria drug does not work and must take full dose.

Contra- indications:
Contraindication are not known clearly.

Pregnancy:
Experience on the human are limited, especially in the early stages of pregnancy. No side effects have meaning in 23 children born of mothers who have used artemether in the period of 16th-38th week of pregnancy. Thus drugs can be used for pregnancy has cerebral malaria or malaria in areas may be complicated caused by multi-resistant Plasmodium falciparum.

Lactation:
Not known how the drug transfer into breast milk. But should stop breastfeeding if the mother is treated with artemether.

ADR:
Using a total dose of 700 mg did not show side effects. Millions of people have used artemether, but no serious harmful effects. Have reported on the changes the test parameters, such as reducing red grid, increased transaminase and changes on electrocardiogram. May occur abdominal pain, nausea, vomiting, diarrhea, and tinnitus. However, these changes are only transient. Have not seen the neurological toxicity in humans.
Dealing with ADR contructions:
The drug dose should be sufficient to protect against recurrence.
When severe malaria, to extend treatment to 7 days.

Dosage and usage:
Only used for adults and children over 6 months old. Be severe malaria or complications:
Method 1:
Day 1: intramuscular 3.2 mg / kg / day, four days after: 1.6 mg / kg / day.
Method 2:
Day 1: intramuscular 3.2 mg / kg / day. After that day intramuscular injection 1.6 mg / kg until the patient can use the pill in oral, swith to use oral or ?nective anti-malaria drugs, but not exceed 7 days.
Only use arthemether once a day. When inject for children, use 1 ml tuberculin syringe, for injecting small doses.

Stability and preservation:
To avoid light, avoid heat, stored at room temperature. If so long in cold temperatures, can be precipitated, but can be melt if left at room temperature. If precipitation does not dissolve completely, must be discarded.

Shelf life:
24 months from the date of manufacture.

Incompatibleness
Artemether can be used in combination with other anti - malaria drugs especially with mefloquin.

Overdose and treatment position
Using overdose, need treatment for symptoms of poisoning in the emergency room. There is no specific antidote.


Ascoaquin 100/300

Presentation:
- Box of 1 blister of 3 yellow tablets and 3 white tablets.
- Box of 1 blister of 6 yellow tablets and 6 white tablets.
- Box of 2 blister of 6 yellow tablets and 6 white tablets.
Compositions:
1. Yellow tablet: Artesunate: 100mg2.
White tablet: Amodiaquine HCl: equivalent to 300 mg amodiaquine base
Excipients:
Microcrystalline cellulose, lactose, amidon, polyvinyl pyrrolidon, erythrosine, sodium glycolat starch, talcum, magnesium stearate, silicon dioxide.q.s 1 tablet

Pharmaceutical form:
Tablet.

Indications:
Ascoaquin 100/300 is indicated for the treatment of severe malaria, cerebral malaria caused by Plasmodium falciparum , including cases being resistant to other antimalarials.

Contraindications:
- Known hypersensitivity to amodiaquine, artesunate, or artemisinin derivatives.
- Liver disorders.
- Pregnant woman with the first trimester of pregnancy.

Precautions:
- This drug contains amodiaquine which is no longer recommended for prophylaxis of Plasmodium falciparum malaria because of being associated with hepatotoxicity, agranulocytosis.
- Large doses of amodiaquine higher than recommended dose have been reported to produce nervous disorders such as syncope, spasticity, convulsions and involuntary movements.
- Amodiaquine may cause blood dyscrasias, haemolytic anaemia, hepatitis, peripheral neuropathy. If long-term therapy is given, regular ophthalmic examination is recommended.
- Because amodiaquine may concentrate in the liver, the drug should be used with caution in patients with hepatic disease or alcoholism and in patients receiving hepatotoxic drugs.
- Patients with glucose 6 - phosphate dehydrogenase deficiency.

Drug Interactions:
- The incidence of agranulocytosis is higher when amodiaquine is combined with other antimalarials. Drug-induced involuntary movements have reported to occur when amodiaquine is combined with chloroquine.
- Magnesium trisilicate and kaolin are known to decrease the gastrointestinal absorption of amodiaquine when administered simultaneously.
- Artesunate has a minimal effect on hepatic cytochrome P450 activity and does not appear to influence the metabolism of mefloquine, a drug likely to be used in combination with artesunate.
- Artesunate does not inhibit the formation of carboxy-primaquine, a metabolite of primaquine.

Pregnancy - Lactation:
- Caution should be observed before administering amodiaquine-artesunate combination in pregnancy as enough safety data is not available.
- It should not be used in pregnancy during the first trimester.
Effect of drug on ability to drive and operate machines
- Effect of drug on ability to drive and operate machine has not reported adequately.

Dosage:
- Children over 13 years of age and adults: 1 white tablet and 1 yellow tablet twice a day for 3 consecutive days.

Side effects:
- Amodiaquine may cause undesired effects such as: Agranulocytosis, blood dyscrasias, haemolytic anaemia, hepatitis, peripheral neuropathy.
- In therapeutic doses used for malaria, amodiaquine may occasionally cause nausea, vomiting, diarrhoea, pruritus, vertigo and lethargy, abdominal pain, headache and photosensitivity.
- If given for long periods, it sometimes causes corneal deposits, visual disturbances and bluish-grey pigmentation of the finger nails, skin and hard palate. These reactions clear somewhat slowly, on stopping treatment. However, because of the occasional development of irreversible retinopathy, regular ophthalmic examinations should be carried out if the drug is used over a long period. The drug can also cause irregular heart beats.
- Artesunate and other related-artemisinin derivatives have not been reported any serious adverse reactions. Drug-induced fever can occur. Cardiotoxic has been observed following administration of high doses.
- Possible artesunate-related side effects include dizziness, itching, vomiting, abdominal pain, flatulence, headache, bodyache, diarrhoea, tinnitus and increased hair loss, macular rash, reduction in neutrophil counts and convulsions. However, it is likely that many of these effects are disease related rather than drug-induced.
Report any side effects to your physician or pharmacist during period of treatment.

Overdose:
- In the amodiaquine - artesunate combination, overdose is mainly pertaining to amodiaquine.
- Intoxication with amodiaquine is far less frequent than chloroquine poisoning. However, large doses of amodiaquine have been reported to produce syncope, spasticity, convulsions and involuntary movements, headache, vertigo and vomiting, drowsiness. The most dramatic feature is cardiovascular disturbance, convulsions, coma, hypotension, impaired respiration, cardiac arrest, hypokalemia, visual disturbance, including sudden loss of vision, which is usually transitory, blurred vision, blindness.
- No data available for overdose of artesunate.

Treatment of overdose:
- Reporting to physician or pharmacist is required as quickly as possible in the event of overdose, event if symptoms of overdose are not presented.

Shelf-life:
36 months from the date of manufacturing.

Storage:
Store in a cool and dry place below 280C, protect from light.

Specification: Manufacturer's.


Ascoaquin 50/153

Presentation:
- Box of 1 blister of 3 yellow tablets and 3 white tablets.
- Box of 1 blister of 6 yellow tablets and 6 white tablets.
- Box of 2 blister of 6 yellow tablets and 6 white tablets.
Composition:
1. Yellow tablet: Artesunate: 50mg
2. White tablet: Amodiaquine HCl: equivalent to 153 mg amodiaquine base
Excipients: .q.s: 1 tablet

Pharmaceutical form:
Tablet.

Indications:
Ascoaquin 50/153 is indicated for the treatment of case of severe malaria, cerebral malaria caused by Plasmodium falciparum, including cases are resistant to other antimalarials.

Contraindications:
- Known hypersensitivity to amodiaquine, artesunate, or artemisinin derivatives.
- Liver disorders.
- Pregnant woman with the first trimester of pregnancy.

Precautions:
- This drug contains amodiaquine which is no longer recommended for prophylaxis of Plasmodium falciparum malaria because of being associated with hepatotoxicity, agranulocytosis.
- Large doses of amodiaquine higher than recommended dose have been reported to produce nervous disorders such as syncope, spasticity, convulsions and involuntary movements.
- Amodiaquine may cause blood dyscrasias, haemolytic anaemia, hepatitis, peripheral neuropathy. If long-term therapy is given, regular ophthalmic examination is recommended.
- Because amodiaquine may concentrate in the liver, the drug should be used with caution in patients with hepatic disease or alcoholism and in patients receiving hepatotoxic drugs.
- Patients with glucose 6 - phosphate dehydrogenase deficiency.

Drug interactions:
- The incidence of agranulocytosis is higher when amodiaquine is combined with other antimalarials. Drug-induced involuntary movements have reported to occur when amodiaquine is combined with chloroquine.
- Magnesium trisilicate and kaolin are known to decrease the gastrointestinal absorption of amodiaquine when administered simultaneously.
- Artesunate has a minimal effect on hepatic cytochrome P450 activity and does not appear to influence the metabolism of mefloquine, a drug likely to be used in combination with artesunate.
- Artesunate does not inhibit the formation of carboxy-primaquine, a metabolite of primaquine.

Pregnancy - Lactation:
- Caution should be observed before administering amodiaquine-artesunate combination in pregnancy as enough safety data is not available.
- It should not be used in pregnancy during the first trimester.

Effect of drug on ability to drive and operate machines:
- Effect of drug on ability to drive and operate machine has not reported adequately.

Dosage
- Ascoquin 50/153 is suitable for children from 7 to 13 years of age
- The recommended dose is 1 yellow tablet and 1 white tablet, twice a day for 3 consecutive days.

Side effects
- Amodiaquine may cause undesired effects such as: Agranulocytosis, blood dyscrasias, haemolytic anaemia, hepatitis, peripheral neuropathy.
- In therapeutic doses used for malaria, amodiaquine may occasionally cause nausea, vomiting, diarrhoea, pruritus, vertigo and lethargy, abdominal pain, headache and photosensitivity.
- If given for long periods, it sometimes causes corneal deposits, visual disturbances and bluish-grey pigmentation of the finger nails, skin and hard palate. These reactions clear somewhat slowly, on stopping treatment. However, because of the occasional development of irreversible retinopathy, regular ophthalmic examinations should be carried out if the drug is used over a long period. The drug can also cause irregular heart beats.
- Artesunate and other related-artemisinin derivatives have not been reported any serious adverse reactions. Drug-induced fever can occur. Cardiotoxic has been observed following administration of high doses.
- Possible artesunate-related side effects include dizziness, itching, vomiting, abdominal pain, flatulence, headache, bodyache, diarrhoea, tinnitus and increased hair loss, macular rash, reduction in neutrophil counts and convulsions. However, it is likely that many of these effects are disease related rather than drug-induced.
Report any side effects to your physician or pharmacist during period of treatment.

Overdose:
- In the amodiaquine - artesunate combination, overdose is mainly pertaining to amodiaquine.
- Intoxication with amodiaquine is far less frequent than chloroquine poisoning. However, large doses of amodiaquine have been reported to produce syncope, spasticity, convulsions and involuntary movements, headache, vertigo and vomiting, drowsiness. The most dramatic feature is cardiovascular disturbance, convulsions, coma, hypotension, impaired respiration, cardiac arrest, hypokalemia, visual disturbance, including sudden loss of vision, which is usually transitory, blurred vision, blindness.
- No data available for overdose of artesunate.

Treatment of overdose:
- Reporting to physician or pharmacist is required as quickly as possible in the event of overdose, event if symptoms of overdose are not presented.

Shelf-life:
36 months from the date of manufacturing.

Storage:
Store in a cool and dry place below 280C, protect from light.

Specification:
Manufacturer's.

Vedico Group

Headquarter Of Regent Road / Leicester Square - IMATT
2 Sahr Johnny Drive
Freetown - Sierra Leone
Phone: +232 766 534 97
E-mail: info(at)vedico.com

Cet In Touch